ArticleBMC musculoskeletal disorders2016
Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts.
Article in BMC musculoskeletal disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Potential role of CTHRC1 in renal fibrosis.Molecular biology reports · 2026Review
- NIMA-related kinase family at the nexus of skeletal development and congenital arthrogryposis: coordinated regulation of cell cycle and ciliary dynamics.Frontiers in genetics · 2026Review
- Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies.The Journal of hand surgery · 2023Review
- Nanostring-Based Identification of the Gene Expression Profile in Trigger Finger Samples.Healthcare (Basel, Switzerland) · 2021Article
- A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases.Cureus · 2021Review
- Current role of the collagenase Clostridium histolyticum in Dupuytren's disease treatment.Irish journal of medical science · 2020Review
- The Role of IL-6 in Skin Fibrosis and Cutaneous Wound Healing.Biomedicines · 2020Review
- Pirfenidone inhibits epithelial-mesenchymal transition in keloid keratinocytes.Burns & trauma · 2020Article
- Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts.BMC musculoskeletal disorders · 2019Article
- Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupuytren's disease (DD) is a complex fibro-proliferative disorder of the hand that is often progressive and eventually can cause contractures of the affected fingers. Transforming growth factor beta (TGF-β
methodsFibroblasts harvested from (DD) and carpal tunnel (CT)- tissues were treated with or without TGF-β
resultsOur results show that PFD effectively inhibits TGF-β
conclusionTaken together these results suggest the PFD can potentially prevent TGF-β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.